FDA accepts NDA for exenatide for once-weekly treatment of type 2 diabetes
Amylin Pharmaceuticals, Eli Lilly and Company, and Alkermes, Inc. announced that the FDA has accepted for review the New Drug Application (NDA) submitted for once-weekly exenatide as a subcutaneous injectable treatment of type 2 diabetes.
Your Email Address:
Recipient(s) Email Address:
(Separate multiple e-mail addresses with commas. Limited to 20 addresses.)
Include a message (optional):
The e-mail address(es) that you supply to use this service will only be used to send the requested article.